International consensus guidance for management of myasthenia gravis: Executive summary.
Neurology
; 87(4): 419-25, 2016 Jul 26.
Article
em En
| MEDLINE
| ID: mdl-27358333
ABSTRACT
OBJECTIVE:
To develop formal consensus-based guidance for the management of myasthenia gravis (MG).METHODS:
In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness methodology was used to develop consensus guidance statements. Definitions were developed for goals of treatment, minimal manifestations, remission, ocular MG, impending crisis, crisis, and refractory MG. An in-person panel meeting then determined 7 treatment topics to be addressed. Initial guidance statements were developed from literature summaries. Three rounds of anonymous e-mail votes were used to attain consensus on guidance statements modified on the basis of panel input.RESULTS:
Guidance statements were developed for symptomatic and immunosuppressive treatments, IV immunoglobulin and plasma exchange, management of impending and manifest myasthenic crisis, thymectomy, juvenile MG, MG associated with antibodies to muscle-specific tyrosine kinase, and MG in pregnancy.CONCLUSION:
This is an international formal consensus of MG experts intended to be a guide for clinicians caring for patients with MG worldwide.
Texto completo:
1
Coleções:
01-internacional
Temas:
Geral
/
Tipos_de_cancer
/
Outros_tipos
Base de dados:
MEDLINE
Assunto principal:
Miastenia Gravis
Tipo de estudo:
Guideline
Limite:
Adult
/
Child
/
Female
/
Humans
/
Pregnancy
Idioma:
En
Revista:
Neurology
Ano de publicação:
2016
Tipo de documento:
Article